Connect with us

Government

From Pistol-Dollar To Petro-Dollar To Pharma-Dollar…

From Pistol-Dollar To Petro-Dollar To Pharma-Dollar…

Published

on

From Pistol-Dollar To Petro-Dollar To Pharma-Dollar... Tyler Durden Mon, 09/28/2020 - 00:00

Authored by Dr. T.P.Wilkinson via GlobalResearch.ca,

In 1973, the world economy was brought almost to a halt by a supposed shortage of oil. The ostensible trigger for this alleged shortage was the so-called Yom Kippur War in which the armed forces of the Anglo-American Empire’s settler-colonial offshore enterprise in Palestine, also known as the State of Israel, repelled the forces of Egypt and Syria, which had moved to reoccupy the territory stolen from them by Israel in the 1967 Six Day War. One response to the Anglo-American Empire’s support of its client state against those states Israel wished to conquer was an oil embargo proclaimed by OPEC, with the largest producer– the autocratic Anglo-American protectorate Saudi Arabia at the lead.

Portrayed in the mainstream Western media as a sign of Arab economic strength – also as anti-Semitism in some quarters – the embargo led to massive economic disruption in all the countries that had to import oil, mainly Europe and its former colonies.

This embargo created the impression of a global oil shortage—which although there was none, could not be overcome without violating the power of the oil cartel. While the OPEC embargo formally restricted the sale of crude oil to Israel’s sponsors, there was no real oil shortage since oil supplies to Europe and the US have always been in the hands of the majors (now super-majors), then known as the “seven sisters”. OPEC’s announcement of an embargo at the well had no impact on the enormous upstream reserves held by the mainly American majors. However it did provide the pretext for massive price increases at the pump– presented as shortage-induced.

Unnoticed except in the aftermath and ignored generally in popular debate or historical literature was the far more insidious deal made secretly while everyone from Bonn to Boston and Lyon to Los Angeles was queuing for petrol or the dole.

In 1971 Richard Nixon had announced that the US dollar would no longer be redeemable for gold – at any price. This decision had been largely induced by the enormous debt incurred funding the US war against Vietnam. In the course of this fateful decision, secret negotiations were undertaken with the Kingdom of Saudi Arabia, which led to an agreement that Saudi Arabia and OPEC would not sell oil in any currency except US dollars.

The oil crisis pushed the price of oil to such heights that many countries in Europe and especially the newly independent countries, soon exhausted their foreign exchange reserves and were compelled to borrow US dollars to pay for oil imports. The result was a boom for the US regime, e.g. oil and banking – not its ordinary citizens – as the demand for US currency led to an inflow of foreign exchange and an overall improvement in its current accounts. Meanwhile the US Treasury could literally print dollars to buy oil– when the time was right.

Even today this story is told in a way to cast aspersions on the Arab states– although all the major oil-producing Arab states involved were and are entirely dependent upon the Anglo-American Empire and its military force for their very survival. It is a false parable used to exaggerate the innocence or helplessness of the settler-colonial state “surrounded” by “ragheads” instead of “redskins” who have all the oil, while poor Israel only has atomic bombs and the biggest foreign aid subsidy per capita of any country the US funds.

Why do I take the trouble here to recount history, which is or ought to be well known– at least to the historically literate?

It is worth recalling here that the Seven Sisters, as they were then called, are actually fewer now due to mergers. The upstream oil industry is still dominated by the Standard Oil companies (yes, Rockefeller, i.e. ExxonMobil) and their allies as well as the Rothschild-Nobel companies. Together they assure that oil prices and distribution are closely controlled– if not absolutely– and that the commerce in oil is billed in the leading currency of the Empire, the US dollar.

The Anglo-American Empire, amazingly similar in composition to the dream of Cecil Rhodes and his personal banker Lord Rothschild, relies not only on oil and the financial transactions connected with it.

There are two other major businesses that support the value of lead currencies, like the USD, GBP or even the EUR. They are war– and hence both legal and illegal arms sales– and drugs, both licit and illicit. All three “markets” are entirely controlled by cartels and state regulation. Moreover they provide windfall profits because they are all addictive and toxic. That means the traders get money and the buyers get garbage.

Stemming from the 19th century Opium Wars, Great Britain became the biggest dope pusher in the world. The opium trade made the British East India Company shareholders and those who traded with and for it wealthy beyond compare. While the US American schoolchild may learn about the Boston Tea Party, in which a few ruffians dumped British East India Tea into the harbour as a protest against taxation like the Townshend Acts[6], they won’t learn that proud New England families not only funded the Ivy League colleges with slave trading but with the income from opium business.

It is essential to recall that every crime is simply the unauthorised version of an activity otherwise deemed legal. The difference between marriage with dowry and prostitution is simply the statute book. The difference between war and murder is the sovereign authorisation. Seagram (Bronfman) produced whiskey in Canada that was legal and sold it more profitably in the US during Prohibition where it was illegal. The leading pharmaceutical companies are the brothers of the heroine, cocaine and synthetics pushers. And between all these folks who are all just merchants, there is the State– the armed bureaucracy that regulates these businesses in accordance with the most powerful to permit each side of these businesses to extract the maximum profit– yes, from us.

That said, as I have written in previous articles, the question of history arises not from the need to find the “true past” but to answer questions in the present. It is the most urgent present question with which I have been preoccupied for the past six months. Why in a global system dominated by the religious ideology of Business and the absolute priority of “the economy” have we seen the leading authorities, autocratic and bureaucratic, suspend the “economy” and disregard Business because of a new, improved version of the seasonal influenza? There are rational and irrational explanations. That is because power may be understood rationally but those who hold and exercise it are often– if not always clinically insane (it is just because they own the clinics and the doctors that no one can utter this diagnosis!).

Again I want to remind the impatient reader– who implicitly strains my patience by not reading or remembering anything longer than the last Facebook or Instagram post– that all meaningful organisational decisions are made in secret by those who have the most power in the organisation– whether it is the classroom in which you send your child to be bullied (or bully) or the workplace you freely attend to earn money to pay the bank for the privilege of living in whatever house they let you buy. If you work in a big enough company or institution your boss and the bank know what your credit future will be like before you do. But never mind this bit of mundane reality. The point is simply nothing of any importance is ever decided in public where you have anything to say about it.

Having gotten that embarrassing sentimentality out of the way, let us consider what has happened since March 2020.

The Pandemic

Following events in China, the OPEC of the pharmaceutical cartel, aka the World Health Organisation (in an earlier article I also wrote that “witch-hunting” is also part of their job), performed some international bureaucratic gymnastics – like several years ago with the so-called “swine flu” – to declare a high grade pandemic phase alert (see table).

This decision was presented as some kind of service to public health — this euphemism is deliberately conflated with concern for the wellbeing of ordinary humans, but is nothing of the sort. To make this quite clear: most genuine public health issues arise from poor nutrition, vile working conditions, polluted air, water and food, and poverty. None of these “pathogens” is part of the WHO brief. The World Health Organisation was established solely to market Western medical products worldwide and at the most profitable rates possible. This means among other things by arranging that poor countries devote precious foreign exchange for the purchase of bulk pharmaceuticals of dubious value under the pretext of being able to treat their indigent populations for illnesses that are almost entirely due to poor nutrition, vile working conditions, polluted air, water and food and poverty. Long before the Bush-Clinton clique promoted “humanitarian interventionism”, the WHO was poisoning the poor for humanitarian purposes (also known as eugenics).

N.B. anyone who has not grasped the consequences of the US regime’s ownership of the UN and its agencies should read the story of the UN in Korea and in the Congo for a start.

But I am digressing if only slightly. OPEC has never included all the oil producing countries and it was only effective as a cartel because it had the deep if covert collaboration of the Anglo-American oil majors. Without the pumps– wholly controlled upstream by either Rockefeller or Rothschild/ Nobel– Saudi oil would have been worthless. While we all imagine that oil is what drives our cars and heats our homes that is in fact a relatively minor and expendable part of the oil economy. Upstream the truly lucrative oil flows into petrochemicals, e.g. plastics, fertilizers, and– guess what, pharmaceuticals! Indeed the oil business, which started with “snake oil”, has never left it. Petroleum, that stuff that sticks to duck feathers and suffocates fish is the same gooey slime that forms the basis of much of the medicine you take. Think about it a minute: Monsanto (now part of IG Farben legacy, Bayer AG) started as a poison producer when the US Army panicked about a potential natural sugar shortage during the Great War and gave John Francis Queeny the inspiration to sell the US Government coal tar as a sweetener. Some readers may recall when saccharine was finally prohibited. However it had been identified as a carcinogen already in the 1920s!

Pharmaceuticals– until the dawn of genetic manipulation, a largely petrochemical or opiate driven product stream– is an integral part of the triad that drives modern capitalism: drugs, oil and guns. The oil industry is tightly held; mainly by two dynastic groups. And surprise, surprise the drug industry is too– the successors to the Anglo-American opium trade dominate the licit pharmaceuticals side and the illicit opium-based and cocaine drug trade. Since these businesses cannot be regulated in boardrooms alone, more than occasional persuasion is needed. So guns are just as important. But the gun trade is a topic for another day.

So what happened in March, really? My previous observations and summaries have not yet been rebutted. Nonetheless I do believe that beyond the obvious manifestations of the West’s confrontation with China, aside from the hyper-policing regime that is being created, there is a useful analogy which is perhaps more powerful than the US regime’s destruction of the New York World Trade Center buildings. That act of armed propaganda by other government agencies was certainly powerful in expanding the police and military power of the degenerate US Empire. However, like the US war against Vietnam it has been extremely expensive. All the president’s accountants and all the president’s lawyers have not been able to put Humpty Dumpty (at least not his bank account) together again.

So like those who tried to command Richard Nixon– and finally deposed him– the ruling class of the Anglo-American Empire is determined to eliminate another “Nixon” outsider (although Nixon always thought he really “belonged”) and restore order. Nixon, like the reigning POTUS, enjoyed wide popular support. However he had lost the support of the Establishment (which has come to be called the “Deep State” so as to imply that there is no Establishment or to lend its overt members legitimacy while denying the means by which it actually exercises power). Nixon actually saved the Establishment but it did not want to be saved by an outsider. It did not want to anyone outside its own exclusive circle. So a pretext was found– and he was dismissed. He knew that the alternative was a “Kennedy solution”.

The present POTUS has been trying to save the US regime from the antagonism of those it has abused both domestically and foreign. He has tried to harness the latent populism– what too many people confuse with “Left”– and channel it back into that revival tent in a way no Oreo Obama could have done– despite his Kennedy plagiarism.

But that is all really a sideshow for the financial disaster that the Reagan-Bush-Clinton dynasty (and its obscene scions in Britain and Germany) left the dying Anglo-American Empire. Nixon presided over the clever back channel negotiations to open China, bring Pepsi to the Soviet Union and save the USD by linking it to oil. Everything indicates that Trump has no clue of any of this– and no one is going to tell him either.

But the USD domination is under attack from all sides, by the weak and the strong. The Empire has been losing its wars but paying its bankers trillions and trillions for that privilege – beyond the capacity of anything the Empire can produce. Without a reinforced US dollar no one in the Empire can imagine the future.

So hark, the sneeze heard around the world.

The WHO assumed the role OPEC played in 1973. It declared a global pandemic under the most spurious conditions with the full knowledge that this would not only permit a shutdown of the economy (for political and economic benefits I have detailed elsewhere) but to create something only logical– the PharmadollarTo keep it poetic, we now have the three P’s of global monetary domination: pistol dollar, followed by the petrodollar and now the pharma-dollar.

An emerging and potentially infinite demand for pharmaceuticals – legal or illegal – safe or unsafe - will offer the Western pharmaceutical cartels untold and unlimited profits and because these are all countries working in the USD / EUR markets, together with the WHO will be guaranteed potentially unlimited profit streams. So from the first circle of hell we descend into the second circle. Can we get any closer to damnation?

Read More

Continue Reading

Government

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide…

Published

on

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide Black Lives Matter riots in the summer of 2020, some elite colleges and universities shredded testing requirements for admission. Several years later, the test-optional admission has yet to produce the promising results for racial and class-based equity that many woke academic institutions wished.

The failure of test-optional admission policies has forced Dartmouth College to reinstate standardized test scores for admission starting next year. This should never have been eliminated, as merit will always prevail. 

"Nearly four years later, having studied the role of testing in our admissions process as well as its value as a predictor of student success at Dartmouth, we are removing the extended pause and reactivating the standardized testing requirement for undergraduate admission, effective with the Class of 2029," Dartmouth wrote in a press release Monday morning. 

"For Dartmouth, the evidence supporting our reactivation of a required testing policy is clear. Our bottom line is simple: we believe a standardized testing requirement will improve—not detract from—our ability to bring the most promising and diverse students to our campus," the elite college said. 

Who would've thought eliminating standardized tests for admission because a fringe minority said they were instruments of racism and a biased system was ever a good idea? 

Also, it doesn't take a rocket scientist to figure this out. More from Dartmouth, who commissioned the research: 

They also found that test scores represent an especially valuable tool to identify high-achieving applicants from low and middle-income backgrounds; who are first-generation college-bound; as well as students from urban and rural backgrounds.

All the colleges and universities that quickly adopted test-optional admissions in 2020 experienced a surge in applications. Perhaps the push for test-optional was under the guise of woke equality but was nothing more than protecting the bottom line for these institutions. 

A glimpse of sanity returns to woke schools: Admit qualified kids. Next up is corporate America and all tiers of the US government. 

Tyler Durden Mon, 02/05/2024 - 17:20

Read More

Continue Reading

International

Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…

Published

on

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading

International

Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….

Published

on

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 

 

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com 


Read More

Continue Reading

Trending